Efficacy and Safety of Pioglitazone Add‐On in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Endocrinology, Diabetes & Metabolism · 2025
DOI: 10.1002/edm2.70061 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2025. Verfasst von Ubaid Khan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Pioglitazone, Diabetes Mellitus, Type 2, Metformin, Benzhydryl Compounds. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Type 2 diabetes mellitus (T2DM) accounts for over 90% of diabetes cases worldwide. Pioglitazone, a thiazolidinedione, enhances insulin sensitivity by activating PPAR‐γ. Evidence on its efficacy and safety as an add‐on to metformin and SGLT2 inhibitors in inadequately controlled T2DM is limited. This systematic review and meta‐analysis evaluates pioglitazone's role as a third‐line therapy for improving glycaemic control in addition to metformin and Dapagliflozin. Methodology We conducted comprehensive searches across PubMed, CENTRAL, WOS, Scopus and EMBASE until December 2024. Pooled data were reported using risk ratio (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes, along with a 95% confidence interval (CI). This systematic review and meta‐analysis is registered with PROSPERO ID: CRD42024612005 .
Results
We included three RCTs with 885 patients. Pioglitazone add‐on therapy significantly reduced HbA1c levels (MD: −0.41; 95% CI: −0.54 to −0.27, p = < 0.00001, I 2 = 0%), fasting blood glucose (MD: −11.91; 95% CI: −16.34 to −7.48, p = < 0.00001, I 2 = 0%), Homeostatic Model Assessment for Insulin Resistance (HOMA‐IR) (MD: −0.65; 95% CI: −1.05 to −0.25, p = 0.001, I 2 = 4.89%), increased the rate of achieving HbA1c < 7% (RR: 2.09; 95% CI: 1.66 to 2.64, p = < 0.00001, I 2 = 0%), and HbA1c < 6.5% (RR: 2.19; 95% CI: 1.36 to 3.53, p = 0.001, I 2 = 0%). However, there was no difference regarding Homeostasis model assessment of β‐cell function (HOMA‐β) between the two groups (MD: 2.73; 95% CI: −5.24 to 10.70, p = 0.5, I 2 = 27.53%).
Conclusion
Pioglitazone add‐on therapy significantly improved glycaemic control by reducing HbA1c, fasting blood glucose and HOMA‐IR while increasing the likelihood of achieving HbA1c targets. However, no significant difference was observed in HOMA‐β between groups. These findings suggest the potential benefit of pioglitazone in enhancing glycaemic outcomes in diabetes management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Department of Medicine, King Edward Medical University, Lahore, Pakistan.
- Department of Medicine, Saidu Medical College, Swat, Pakistan.
- Emergency Medicine Department, Al-Bank Al-Ahly Hospital, Cairo, Egypt.
- Faculty of Medicine, Mansoura University, Mansoura, Egypt.
- Department of Radiology, Pakistan Atomic Energy Commission Hospital, Islamabad, Pakistan.
ORCID-Profile: Ubaid Khan, Muhammad Haris Khan, Ahmed Raza, Mustafa Turkmani
Zitieren
APA
Khan, U., Majeed, Z., Khan, M. H., Elsnhory, A. B., Amin, A. M., Nawaz, A., Raza, A., Siddque, H. M. W., Turkmani, M., & Abuelazm, M. (2025). Efficacy and Safety of Pioglitazone Add‐On in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70061
Vancouver
Khan U, Majeed Z, Khan MH, Elsnhory AB, Amin AM, Nawaz A, et al. Efficacy and Safety of Pioglitazone Add‐On in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Endocrinology, Diabetes & Metabolism. 2025. doi:10.1002/edm2.70061
BibTeX
@article{Khan2025,
author = {Khan, Ubaid and Majeed, Zuhair and Khan, Muhammad Haris and Elsnhory, Ahmed Bostamy and Amin, Ahmed Mazen and Nawaz, Anum and Raza, Ahmed and Siddque, Hafiz Muhammad Waqas and Turkmani, Mustafa and Abuelazm, Mohamed},
title = {Efficacy and Safety of Pioglitazone Add‐On in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2025},
doi = {10.1002/edm2.70061}
}
EUVIMED